Loading…
Loading…
PEAK (Healthpeak Properties, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PEAK and 80,000+ other tickers.
See exactly how PEAK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PEAK and 80,000+ other tickers.
Healthpeak Properties, Inc., an S&P 500 constituent, operates as a fully integrated real estate investment trust (REIT). The company specializes in the acquisition and development of premium properties across three private-pay healthcare segments: Life Science, Medical Office, and Senior Housing. This focus is meticulously crafted to deliver stability amidst the cyclical nature of the industry. Healthpeak leverages its profound expertise in the healthcare property market, coupled with an ambitious outlook for sustained, long-term expansion.
First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 release Completion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in 4Q 2026, with topline clinical data release anticipated in 2Q 2027 PALO ALTO, Calif., Aug. 6, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting Pivotal Analysis 1 of the KSI-101 Phase 3 program in macular edema secondary to inflammation ("MESI").
New Linux Foundation and first open-source metadata server advances parallel file system design with an elastic architecture for AI and HPC storage at scale New Linux Foundation and first open-source metadata server advances parallel file system design with an elastic architecture for AI and HPC storage at scale
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p
WALTHAM, Mass. and BOULDER, Colo.
The Next Evolution in F45 Training Performance Events Launches Network-Wide with Red Bull as Global Partner The Next Evolution in F45 Training Performance Events Launches Network-Wide with Red Bull as Global Partner